Zoetis Inc (NYSE:ZTS)
| 164.25 Delayed Data As of Mar 24 |  +3.01 / +1.87%Today’s Change | 124.15 Today|||52-Week Range 201.32 | +12.08% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $76.1B |
Company Description
Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. The United States segment is involved in U.S. market and regulatory activities. The International segment includes non-U.S. market and regulatory activities. The company was founded in 1952 and is headquartered in Parsippany, NJ.
Contact Information
Zoetis, Inc. 10 Sylvan Way Parsippany New Jersey 07054 |
Employees
Shareholders
| Mutual fund holders | 49.29% |
| Other institutional | 44.71% |
| Individual stakeholders | 27.76% |
Top Executives
| Kristin C. Peck | Chief Executive Officer & Director |
| Roxanne Lagano | Chief Human Resources Officer & Executive VP |
| Wetteny Joseph | CFO, EVP & Head-Business Development |
| Mike McFarland | Chief Medical Officer & Executive Vice President |
| Robert J. Polzer | President-Research & Development, Executive VP |
